Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.31 USD | -7.97% | -5.33% | -45.13% |
Apr. 25 | Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4 | MT |
Apr. 25 | CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.13% | 562M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- CureVac To Begin Trials Of COVID-19 Vaccine As Animal Testing Shows Strong Antibody Response